Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of short peptide to preparation of immunoregulation medicament

A short peptide and drug technology, applied in the field of biomedicine, can solve the problems of poor stability and shortened half-life

Active Publication Date: 2018-10-23
SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As the length of the polypeptide increases, its stability and half-life in vivo are correspondingly reduced or shortened

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of short peptide to preparation of immunoregulation medicament
  • Application of short peptide to preparation of immunoregulation medicament
  • Application of short peptide to preparation of immunoregulation medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Example 1, miPEP155 sequence analysis and in vitro synthesis

[0080] 1. miPEP155 sequence analysis

[0081] The sequence of miR-155 host gene is as follows:

[0082]

[0083]

[0084] In the above sequence, the underlined part in italics is the predicted sequence of miPEP155. The sequence translated into amino acid is: MEMALMVAQTRKGKSVV (SEQ ID NO: 2).

[0085] 2. In vitro synthesis of miPEP155

[0086] Using the conventional solid-phase peptide synthesis method, the peptide was synthesized according to the amino acid sequence of SEQ ID NO: 2, and the mass spectrometry analysis determined that the amino acid was correct as figure 1 A (miPEP155). The purity is 95.1%, as figure 1 b. Dissolve in ddH before use 2 O Standby.

Embodiment 2

[0087] Example 2, expression of miPEP155 in cells

[0088] The coding sequence of miPEP155 was constructed into the BamHI / XhoI restriction site of plasmid pcDNA3.1(+). Thus, the obtained recombinant plasmid can form the fusion protein of miPEP155 and his-tag after expression, and the sequence of the recombinant plasmid is confirmed to be correct after sequencing, as shown in figure 2 a.

[0089] The recombinant plasmid obtained above was transfected into a human kidney epithelial cell line (293T), and the human kidney epithelial cell line (293T) transformed with an empty plasmid pcDNA3.1(+) was used as a control. The blank group was only transfected with pcDNA3.1(+) plasmid, and the miPEP155 group was transfected with miPEP-histag plasmid. Immunofluorescence microscopy was used to observe the expression of miPEP-histag protein. The result is as figure 2 B, miPEP-histag protein is mainly expressed in the envelope and cytoplasm of 293T cells.

Embodiment 3

[0090] Example 3, miPEP155 inhibits Th17 cell differentiation

[0091] The miPEP155 obtained by the solid-phase peptide synthesis method in Example 1 was tested for its effect on Th17 cell differentiation.

[0092] Obtain mouse spleen cells and isolate mice using immunomagnetic beads CD4+ T cells were cultured in 1640 medium at 37°C, and anti-CD3 (5 μg / ml), anti-CD28 (2 μg / ml), TFG-β (10 ng / ml), IL -23 (20 ng / ml), anti-IL-4 (5 μg / ml), anti-IFN-γ (10 μg / ml) were cultured for 3 days to obtain Th17.

[0093] Th17 cells were cultured in 1640 medium at 37°C, divided into several culture groups, and miPEP155 at concentrations of 0 μM, 0.1 μM, 1 μM and 10 μM were added, and the effect of miPEP155 on Th17 differentiation was observed by flow cytometry.

[0094] The result is as image 3 , miPEP155 can significantly inhibit the differentiation of Th17 induced in vitro.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a short peptide miPEP155 to preparation of an immunoregulation medicament. The short peptide is derived from a host gene of micro RNA155, and is named as miPEP155. The miPEP155 polypeptide can restrain the differentiation of Th17 cells, has an immunoregulation function, and can be used for preventing or treating autoimmune diseases.

Description

technical field [0001] The invention belongs to the field of biomedicine, and more specifically, the invention relates to the application of short peptide miPEP155 in the preparation of immunomodulatory drugs. Background technique [0002] Th17 cells (T helper cell17, Th17) are a newly discovered T cell subset capable of secreting interleukin 17 (interleukin 17, IL-17), Th17 is differentiated by T0 cells under the stimulation of IL-6 and IL-23 Helper T cells, RORγ is an important transcription factor. Th17 cells can secrete and produce IL-17A, IL-17F, IL-6 and tumor necrosis factor a (tumor necrosis factora, TNF-a), etc. These cytokines can collectively mobilize, recruit and activate neutrophils, thus effectively It mediates the inflammatory response of tissues, so Th17 plays an important role in autoimmune diseases and body defense responses. [0003] Studies have shown that Th17 is closely related to autoimmune diseases such as psoriasis, autoimmune encephalitis, asthma,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/08C12N15/11A61K38/10A61P37/02A61P17/06A61P17/00A61P25/00A61P19/02A61P11/06
CPCA61K38/00A61P11/06A61P17/00A61P17/06A61P19/02A61P25/00A61P37/02C07K7/08
Inventor 王宏林牛立慢孙洋
Owner SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com